Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
As we continue to debate the proper size and role of government in society, cast your eyes on recent polls by Gallup and Pew that found the majority of Americans felt their income tax was fair.
Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark's genetic therapy for rare blindness costs $850,000
Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets
From gift bans to Google Assistant, POC to OPDP, MM&M staff members give their predictions on what to expect in healthcare marketing in 2018
Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business
Although it's a long way from the president's desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life sciences industry and its marketing partners.
Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds
FDA approves first Apple Watch health accessory; medical charity shared data with pharma donors; FDA approves opioid-addiction treatment
FDA to change Risk Evaluation Mitigation Strategies to prevent delayed generic approvals; Ohio rejects drug-price measure; Aetna CEO wants to improve in-person pharmacy experience
Drug industry spends nearly $50 million to fight drug-price referendum; Novartis weighs sales of generic unit; ICER to evaluate all newly approved drugs
Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs
Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.
AbbVie adds context to CEO's comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico
Patient assistance nonprofit contacted in Aegerion probe; most heavily marketed drugs in Canada offer little therapeutic value; the FDA pans Duchenne drug
FDA closes pediatric study loophole; little evidence outcomes-based contracts are working; PBMs lobby against transparency efforts
Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
Pfizer develops Minecraft version for kids with hemophilia; Lilly to resubmit baricitinib to the FDA; pricing expert says Novartis CAR-T value contract is 'progress'
Nonprofits receive FDA approval for Chagas drug; Gilead's buyout of Kite will put it back in pricing fray; most cancer patients don't receive fertility info
Doctors fret about price of Novartis' experimental CAR-T therapy; study finds digital pillboxes don't improve adherence; India awards Pfizer vaccine patent
Lawmakers to investigate pricing of MS drugs; Mylan will pay $465 million to resolve EpiPen allegations; the FDA approves Pfizer's new cancer drug
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
Gottlieb criticizes drugmakers for 'gaming the system' on generics; investors ignore Trump's pharma criticism; docs are more supportive of single payer
It's not often that pharmaceutical companies are held up as examples of morality or leadership to the general public.
That's why the Coalition for Healthcare Communication is focused on creating self-regulatory guidelines.
What's holding back value-based pricing deals from moving beyond the pilot phase?
The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.
Though Shkreli may soon slip from the public eye, separated from his Twitter account and prohibited from trading securities, pharma communicators must learn from these events.